Novartis' Sandoz dips on debut after lower than expected valuation
[1/2] The company's logo is seen at the cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing Rights Oct 4 (Reuters) - Sandoz (SDZ.S) shares dipped on their market debut on Wednesday after the generic…#stein #switzerland #deutschebank #sandoz #novartis #jefferies #alcon #schottpharma #frankfurt #thyssenkruppnucera (Source: Reuters: Health)
Source: Reuters: Health - October 4, 2023 Category: Consumer Health News Source Type: news
Cell and Gene Therapy Clinical Trials' Regulatory Strategies and Safety Considerations, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insights into how to successfully navigate the regulatory framework for novel interventional agents. Attendees will understand agency expectations on the adequacy of information to support the conduct of clinical studies. Attendees will effectively manage unique... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 4, 2023 Category: Pharmaceuticals Tags: FVT Source Type: news
Xtalks Announces its Life Science Webinar Calendar for October 2023
Upcoming free, educational webinars from Xtalks will feature topics on biomarkers, cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, fundamental research, healthcare, laboratory technology, medical device, patient recruitment & retention,... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 2, 2023 Category: Pharmaceuticals Tags: SVY Source Type: news
Which Gene Therapy Delivery Vector Will Emerge Victorious?
In the race to deliver successful gene therapies, frontrunner AAVs come head to head with underdog lipid nanoparticles. (Source: The Scientist)
Source: The Scientist - October 2, 2023 Category: Science Tags: Magazine Issue Source Type: news
'We've hit the nadir': Penn's Dr. James Wilson sees brighter days ahead for cell and gene therapy
Penn's cell and gene therapy pioneer doesn't believe the dramatic slowdown in investment capital to the sector can get any worse. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 28, 2023 Category: Biotechnology Authors: John George Source Type: news
FDA Panel Overwhelmingly Rejects ALS Cell Therapy
(MedPage Today) -- Nearly all members of an FDA advisory panel voted against the data presented for an investigational amyotrophic lateral sclerosis (ALS) treatment on Wednesday.
In a 17-1 vote, the FDA's Cellular, Tissue, and Gene Therapy Advisory... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - September 28, 2023 Category: Neurology Source Type: news
Base Pair Bio Receives Grant from NIH to Help Deliver Therapies for Genetic Heart Disease
Base Pair Biotechnologies, "The Aptamer Discovery Company™" has been recently awarded a grant from NIH entitled, "Aptamer engineering of lentiviral vectors for cardiac gene therapies". HOUSTON, Sept. 27, 2023 /PRNewswire-PRWeb/ -- Hypertrophic cardiomyopathy (HCM) is the leading cause of... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 28, 2023 Category: Pharmaceuticals Source Type: news
In Mice, Gene Therapy Helps Restore Movement After Spinal Cord Injury
WEDNESDAY, Sept. 27, 2023 -- Gene therapy has restored mobility in mice with completely severed spinal cords, researchers report.
The mice regained the ability to walk, with gait patterns resembling those of mice that resumed walking naturally... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 27, 2023 Category: General Medicine Source Type: news
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
PDUFA date set for March 18, 2024
OTL-200 would be the first and only treatment in the U.S. for early-onset MLD
Previously published data demonstrated administration of one-time gene therapy enables sustained preservation of motor function and... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 18, 2023 Category: Drugs & Pharmacology Source Type: news
Penn spinout founded by Carl June emerges from stealth mode with $18M in funding
BlueWhale Bio was founded with a technology platform to address and overcome bottlenecks in the cell and gene therapy manufacturing process. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 8, 2023 Category: Biotechnology Authors: John George Source Type: news
enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer
BOSTON and MONTREAL, Sept. 7, 2023 -- (Healthcare Sales & Marketing Network) - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs,... Biopharmaceuticals, Personnel enGene, Dually Derivatized Oligochitosan (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2023 Category: Pharmaceuticals Source Type: news
Form D Friday: Dallas biotech Taysha Gene Therapies raises $150 million
See which local firms and funds are raising capital, including a Dallas-based biotech company and two Southlake-based firms, in this week's edition of Form D Friday. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 1, 2023 Category: Biotechnology Authors: Holden Wilen Source Type: news
Gene-Tweaked Stem Cells Offer Hope Against Sickle Cell Disease
THURSDAY, Aug. 31, 2023 -- A type of gene therapy that precisely " edits " a key bit of DNA might offer a new way to treat sickle cell disease -- a painful inherited condition that largely strikes Black children and adults.
That ' s according to a new... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 31, 2023 Category: General Medicine Source Type: news
Behavior Is a Miracle Drug for Our Health
Healthcare is broken. Chronic diseases are eating up an increasing share of healthcare resources in every healthcare system across the world in ways that are not sustainable. Yes, there is a golden age of innovation happening in the form of new technologies like gene therapy, neural technology, immunotherapy, and increasingly the impact of AI on diagnoses and drug development, but we can’t let these extraordinary technological advances blind us to the tragedy of modern healthcare and to the much neglected miracle drug right in front of us: our daily behaviors. Whether for preventing disease or optimizing the treatmen...
Source: TIME: Health - August 31, 2023 Category: Consumer Health News Authors: Arianna Huffington Tags: Uncategorized freelance Source Type: news
An aqueduct connecting the brain to the ear may make gene therapy for hearing loss less invasive.
(Source: The Scientist)
Source: The Scientist - August 28, 2023 Category: Science Tags: News News & Opinion Source Type: news
